

Biomolecular Life Holdings, Inc. (OTC: BIOM) Announces Form 10 Effectiveness and Transition to SEC Reporting Company Status

MIAMI, FLORIDA — October 26, 2026 — Biomolecular Life Holdings, Inc. (OTC: BIOM) ("Biomolecular Life" or the "Company"), a next-generation wellness and longevity technology company focused on human and companion-animal health, today announced that its Form 10 registration statement filed with the U.S. Securities and Exchange Commission (SEC) has become effective, marking a significant milestone in the Company's corporate development and transition to SEC reporting company status.

The effectiveness of the Form 10 represents an important step in Biomolecular Life's commitment to corporate transparency, regulatory compliance, and enhanced communication with shareholders and the investment community.

A Significant Milestone in Corporate Development

Achieving effective Form 10 registration represents an important advancement in the Company's public-company reporting framework. As an SEC reporting company, Biomolecular Life is subject to applicable periodic reporting and disclosure obligations under federal securities laws.

The Company believes that maintaining transparent disclosures, strengthening corporate governance practices, and providing shareholders with access to material corporate information are essential components of building a sustainable public company.

This milestone reflects the Company's ongoing efforts to strengthen its corporate infrastructure and establish a foundation for its long-term business objectives.

Advancing a Next-Generation Wellness and Longevity Platform

Biomolecular Life Holdings, Inc. is focused on developing an integrated wellness platform centered on biomolecular science, precision cellular nutrition, regenerative wellness technologies, and personalized longevity solutions for humans and companion animals.

The Company's strategic vision encompasses the development and commercialization of innovative wellness products, premium nutraceutical formulations, and health optimization solutions designed to support vitality, healthy aging, and overall well-being.

Through its human and animal longevity initiatives, Biomolecular Life seeks to serve consumers, health professionals, specialized wellness facilities, and companion-animal owners through an integrated approach to preventive wellness and healthspan optimization.

Investor Perspective

Biomolecular Life Holdings is being developed as more than a supplement company or wellness technology brand. The objective is to create a scalable longevity ecosystem in which personalized protocols, advanced wellness technologies, nutraceuticals, and future biomolecular innovations reinforce one another.

This integrated model gives BIOM the potential to generate revenue through multiple channels, including direct-to-consumer products, professional wellness applications, technology licensing, strategic partnerships, longevity centers, and companion-animal wellness.

The long-term opportunity is to build a recognizable global platform around one of the fastest-growing areas of consumer health: personalized longevity and health optimization.

The Company intends to continue advancing its business initiatives while strengthening its public-company reporting infrastructure and maintaining appropriate disclosure practices.

Commitment to Transparency and Shareholder Communication

Biomolecular Life recognizes that responsible corporate governance and consistent disclosure are important to shareholder confidence and the long-term development of its business.

With its Form 10 now effective, the Company will continue meeting its applicable SEC reporting obligations and providing material corporate updates through appropriate public disclosure channels.

The Company believes that this milestone establishes an important foundation for its continued corporate development as it pursues its strategic objectives in the evolving wellness and longevity sector.

About Biomolecular Life Holdings, Inc.

Biomolecular Life Holdings, Inc. (OTC: BIOM) is building a wellness platform and creating a longevity technology company focused on human and companion-animal cell nutrition through biomolecular science, precision supplements, regenerative wellness technologies, and personalized health optimization solutions.

BIOM's vision reaches beyond traditional nutritional supplementation.

Through its existing marketing relationship with affiliated Biomolecular Life LLC, the Company participates in the commercial development of human and companion-animal wellness brands.

BIOM provides marketing, advertising, and brand management services in the human and companion-animal wellness sector. The Company intends to pursue additional commercial opportunities in the evolving wellness and longevity markets.

Looking ahead, BIOM intends to explore broader commercial opportunities, including new brand relationships, strategic partnerships, innovative wellness product formats, and expanded distribution channels. Its longer-term strategy includes evaluating opportunities to develop, acquire or license

proprietary brands and related intellectual property, and building biomolecular wellness centers, subject to available capital, commercial feasibility and future agreements. These initiatives are intended to create additional potential revenue sources.

The long-term ambition is to create a scalable commercial platform capable of connecting emerging wellness concepts with consumers seeking more personalized approaches to vitality, longevity, and healthy aging.

The Company's mission is to advance innovative wellness solutions that support healthspan, vitality, and quality of life for people and their companion animals.

For additional information, please visit:

Website: www.biomolecularlifeinc.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, but are not limited to, the Company's business strategy, growth objectives, product development plans, anticipated business opportunities, and future corporate development. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

The effectiveness of the Company's Form 10 does not constitute SEC approval or endorsement of the Company, its business, or its securities. Investors should review the Company's public filings for information regarding its business, financial condition, risk factors, and other material disclosures.

The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

Media and Investor Relations

Email: info@biomolecularlife.com

Phone: 877-646-4833

Biomolecular Life Holdings, Inc.

1395 Brickell Ave., Suite 800, Miami, FL 33131

Website: www.biomolecularlifeinc.com

Ticker: OTC: BIOM

###